Loading
FGF19 (Fibroblast growth factor 19) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma and Ovarian cancer.
Involved in the suppression of bile acid biosynthesis through down-regulation of CYP7A1 expression, following positive regulation of the JNK and ERK1/2 cascades. Stimulates glucose uptake in adipocytes. Activity requires the presence of KLB and FGFR4.
CIViC holds 5 clinical evidence items and 0 assertions across 4 variants, naming Sorafenib, FGFR4 Inhibitor H3B-6527 and Fisogatinib.
In plain words · FGF19 (Fibroblast growth factor 19) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma and Ovarian cancer.
FGF19 (Fibroblast growth factor 19) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma and Ovarian cancer.
Involved in the suppression of bile acid biosynthesis through down-regulation of CYP7A1 expression, following positive regulation of the JNK and ERK1/2 cascades. Stimulates glucose uptake in adipocytes.
No product in this corpus aims at FGF19 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the roles drug-target, biomarker; HPA finds the RNA tissue enriched, which says where the protein sits but not whether the tumour differs from normal tissue. HPA FGF19: RNA tissue enriched (gallbladder 223 nTPM); high antibody staining in 6 normal tissues; highest cancer staining head and neck cancer (1 of 4 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Hepatocellular carcinoma, Ovarian cancer); Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas FGF19 tissue; Open Targets ENSG00000162344 associations
First described 1999. Earliest sequence paper UniProt cites for the protein: Nishimura et al, Biochim. Biophys. Acta, 1999, "Structure and expression of a novel human FGF, FGF-19, expressed in the fetal brain". Source.
Sources: HGNC HGNC:3675 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O95750 (protein name, function text, keywords and locations (REST API)); CIViC gene FGF19 (5 evidence items, 0 assertions, 4 variants; diseases: Hepatocellular Carcinoma, Ovarian Cancer (GraphQL API, CC0))
Involved in the suppression of bile acid biosynthesis through down-regulation of CYP7A1 expression, following positive regulation of the JNK and ERK1/2 cascades. Stimulates glucose uptake in adipocytes. Activity requires the presence of KLB and FGFR4. Location: Secreted (UniProt). Locus 11q13.3 (HGNC).
RNA: tissue enriched (gallbladder 223 nTPM), detected in some normal tissues.
Medium: Appendix, Bronchus, Cerebral cortex, Cervix, Colon, Endometrium, Esophagus, Fallopian tube.
Medium only: breast cancer, carcinoid, cervical cancer, colorectal cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"FGF19" OR ABSTRACT:"FGF19" OR TITLE:"fibroblast growth factor 19" OR ABSTRACT:"fibroblast growth factor 19" OR TITLE:"Fibroblast growth factor 19" OR ABSTRACT:"Fibroblast growth factor 19") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FGF19, not a curated reading list.